Betruger wrote:williatw wrote: Large pharma is not interested.
Ha! How will they
not be interested once it's profitable?
This perhaps is instructive:
http://en.wikipedia.org/wiki/Apo-A1_Milano
A mutant form of "good" cholesterol that removed plaque from arteries, basically reversing the process that put the plaque on the arteries in the 1st place.
http://content.time.com/time/subscriber ... 54,00.html
Health: Drano For The Heart
An experimental drug no one expected to work is surprisingly effective at rooting out cholesterol
By Michael D. Lemonick Monday, Nov. 17, 2003
When they signed up for this week's annual conference of the American Heart Association in Orlando, Fla., thousands of doctors, scientists and pharmaceutical-company reps knew that they would be hearing about the very latest research into the causes of heart disease and the potential treatments. What they probably didn't suspect was that the meeting rooms and hallways would be abuzz with news that broke before the gathering even began--news that may signal an entirely new approach to fighting the nation's leading cause of death.
By infusing patients with an experimental drug, reported Dr. Steven Nissen of the Cleveland Clinic in last week's Journal of the American Medical Association, he and his colleagues reduced the fatty arterial plaque that triggers most heart attacks by an average of 4.2%--about 10 times better than statins, the most effective drugs now on the market, and in the almost unbelievably short period of just five weeks. With only 47 patients, the study was too small to be definitive, but, says Dr. Daniel Rader, the University of Pennsylvania cardiologist who wrote an accompanying editorial in J.A.M.A., "it's very exciting for the field. It's something that I think no one expected. It really has everyone scratching their heads."
Sounds exciting right? How come nothing came of it...well from the 1st link:
Hoping to develop a more effective treatment than their current product Lipitor, Pfizer purchased and internalized Esperion shortly before JAMA published the results of the Apo A-1 Milano trial.[citation needed]
Currently, no drugs based on ApoA-1 Milano are commercially available. Rights to ApoA-1 Milano were acquired in 2003 by Pfizer. Clinically known as ETC-216, Pfizer did not move trials forward, probably because the complex protein is very expensive to produce and must be administered intravenously, limiting its application compared to oral medications
In other words when Pfizer (big pharma) allegedly encountered the road block they abandoned all interest...couldn't be because it competed with their existing statin drugs like Lipitor could it? This would literally remove plaque from blood vessels effectively presumably curing heart disease. Not like statin drugs that merely lower cholesterol, (not necessarily preventing heart disease) and only as long as you keep taking it. One (the cure) would eliminate their source of revenue ultimately the other (statins) an open ended source of revenue.
Perhaps this will bear fruit at some point also from 1st link:
Subsequent Development
Pfizer, after the CETP agent torcetrapib failed in a large human safety trial, decided to exit the cardiovascular market in 2008, though they continue to market Lipitor aggressively.
Esperion, divested by Pfizer in 2008,[10] is back in business and continue to work on HDL mimetic therapies.[11] The company established an agreement with TransGenRx as a protein source.[12]
Calgary-based SemBioSys Genetics Inc. was a biotechnology company that was using Safflower to develop commercial quantities of ApoA-1 Milano.[citation needed] On October 11, 2011 SemBioSys Genetics signed a multi-product commercialization and platform collaboration agreement with Tasly Pharmaceuticals of Tianjin China. In May 2012, SemBioSys terminated its operations and announced that Tasly had terminated their agreement.[13]
On 22 December 2009 The Medicines Company [1] announced it had entered into an exclusive worldwide licensing agreement with Pfizer Inc. for ApoA-I Milano which it then renamed MDCO-216.[14][15]
On the 12th of July 2010 The Medicines Company signed a pharmaceutical development and manufacturing contract with OctoPlus (Netherlands-based drug delivery and drug development company) to perform process development and clinical manufacturing of MDCO-216.[16] The Medicines Company expects to commence clinical studies sometime in 2011. [17]
Cardigant Medical is a Los Angeles based biotech company currently working to commercialize ApoA-1 Milano to treat various vascular diseases
This might generate more interest in them for the ApoA-I Milano:
Loss of Lipitor patent cuts Pfizer net income almost in half
NEW YORK (AP) – Pfizer (PFE) said Tuesday that its fourth-quarter profit fell by half due to one-time charges and a drop in U.S. revenue, which was hurt by blockbuster cholesterol drug Lipitor losing patent protection
http://usatoday30.usatoday.com/money/co ... 52898124/1